Recent CDMO partnerships include COVID-19 collaborations, manufacturing partnerships, service agreements, and a strategic alliance expansion.
Collaboration between contract development and manufacturing organizations (CDMOs) is often necessary to reach certain manufacturing and development goals. The following is a sampling of recent CDMO partnerships in 2021 so far.
Read this article in BioPharm International’s Partnerships for Outsourcing May 2021 eBook.
Lauren Lavelle is assistant editor for BioPharm International.
BioPharm International
eBook: Partnerships for Outsourcing, May 2021
May 2021
Pages: 34–38
When referring to this article, please cite it as L. Lavelle, “CDMO Partnerships Boost Company Capabilities," BioPharm International Partnerships for Outsourcing eBook (May 2021).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.